Daniel Camardo, MBA, Chief Executive Officer

Mr. Camardo joined Athersys in February 2022 as our Chief Executive Officer. Prior to him joining the team, Mr. Camardo served as Executive Vice President and Head of the Rare Disease and Inflammation Business Units and President, U.S. at Horizon Therapeutics (Horizon). In this previous role, Mr. Camardo led a broad commercial transformation, built out new capabilities to support a portfolio of products in the rare disease and specialty medicines space, and helped transform the small specialty products company into a global biotechnology company focused on rare, autoimmune, and severe inflammatory diseases. He has worked in commercial leadership roles for other biotechnology and pharmaceutical companies, including Astellas and has been involved in more than 10 medicine launches across various therapeutic areas, including small molecules and biologics. Mr. Camardo is recognized for creating innovative solutions to overcome marketplace challenges and fostering cross-functional collaboration to drive results. Mr. Camardo holds a Bachelor of Arts degree in Economics and Mathematics from the University of Rochester and a Master of Business Administration from Northwestern University’s Kellogg School of Management.


Maia Hansen, MBA, MS, Chief Operating Officer

Ms. Hansen joined Athersys in 2020 as Senior Vice President of Operations and Supply Chain, and in June 2022 was promoted to Chief Operating Officer. Ms. Hansen has extensive operations and supply chain experience in the pharmaceutical, medical device and consumer health sectors. Prior to joining Athersys, Ms. Hansen was a Senior Partner at McKinsey & Company, a global management consulting firm. She worked with clients around the world to develop and optimize end-to-end operations and global supply chains. Her work included the development of operations and supply chain strategy, capability building, manufacturing optimization, go-to-market effectiveness, and digital and analytics. She was a leader within McKinsey’s Operations practice and led the operations transformation and capability building service line to ensure impact across large-scale operations. In addition, Ms. Hansen served as the Managing Partner of McKinsey’s Cleveland office.

Ms. Hansen served as a Lieutenant with the United States Navy and holds two Bachelor of Science degrees, a Master of Science degree, and a Master of Business Administration, all received from the Massachusetts Institute of Technology.


Kasey Rosado, Interim Chief Financial Officer

Ms. Rosado joined Athersys as interim Chief Financial Officer in August 2022. Ms. Rosado has over 18 years of financial, operational and leadership experience. As Senior Managing Director at Ankura, she provides advisory support for dozens of companies, specializing in financial and operational turnarounds.

Prior to Ankura, Ms. Rosado served as a managing director at CDG Group, where she specialized in advising clients in evaluating, developing and executing financial and strategic alternatives. She played an integral role in helping clients streamline processes across key functional departments to increase visibility and accountability, while focusing on measurability and profitability. Prior to CDG Group, Ms. Rosado was with PricewaterhouseCoopers where she specialized in assisting companies and their creditors in financial restructurings and operational turnarounds.


Robert (Willie) Mays, PhD, Executive Vice President,
Head of Regenerative Medicine &
Neuroscience Programs

Dr. Mays is the Head of Neurosciences and Vice President of Regenerative Medicine at Athersys, Inc. He is focused on the company’s novel adult human stem cell product, MultiStem®, and its applications in Regenerative Medicine and drug discovery, with a specific focus on injuries and diseases affecting the central nervous system. Dr. Mays was the Principal Investigator of the MASTERS (MultiStem Administration for Stroke Treatment and Enhanced Recovery Study) clinical trial assessing the safety and efficacy of MultiStem in the treatment of ischemic stroke. He is also the Principal Investigator of the pivotal Phase III MASTERS-2 study, which has received RMAT, Fast Track and Special Protocol Assessment designations from the FDA. Dr. Mays is a member of the National Center for Regenerative Medicine, Center for Stem Cell and Regenerative Medicine, the American Heart Association, and an Adjunct Professor at the Case Western Reserve University School of Medicine. He has authored or co-authored >30 peer-reviewed scientific papers or reviews and is the inventor of more than 15 patents relating to the use of stem cells for treating disease. Dr. Mays is the Co-chair of the Neuroscience Committee for the International Society for Cellular Therapy, and previously the Board of Directors for the United Cerebral Palsy Foundation of Cleveland and the scientific advisory board for the Children’s Neurobiological Solutions Network in Los Angeles. He graduated from Carnegie Mellon in 1987 with a B.S. in Cell and Developmental Biology.


Manal Morsy, MD, PhD, MBA, Executive Vice President,
Head of Global Regulatory Affairs

Dr. Morsy joined Athersys in 2013 as Vice President and Head of Global Regulatory Affairs and has served as our Senior Vice President and Head of Global Regulatory Affairs since September 2016. She is responsible for the global regulatory activities for the Company’s therapeutic programs, including its MultiStem® cell therapy. Prior to joining Athersys, Dr. Morsy served as Vice President at PTC Therapeutics, Inc. since 2007 where she led global regulatory affairs, developed the company’s regulatory capabilities and was responsible for regulatory activities for multiple programs in several therapeutic areas, including the programs for treatment of Duchene muscular dystrophy and cystic fibrosis using Ataluren, the company’s lead product candidate. Prior to joining PTC, Dr. Morsy spent three years at Tibotec / J&J, serving as Senior Director, Global Regulatory Affairs, where she was responsible for global regulatory activities for the company’s pediatric development programs, the tuberculosis and the HIV (Prezista) programs. Previous to her tenure at Tibotec, Dr. Morsy served as Director of Worldwide Regulatory Affairs for Merck & Co., where she led and supported new regulatory filings in the US and abroad, as well as supplemental filings for previously approved products. Dr. Morsy received her MD degree from the University of Alexandria, Faculty of Medicine, Egypt; her PhD from the Eastern Virginia Medical School/Old Dominion University in Norfolk, VA; and her MBA from the LeBow Business School, Drexel University in Philadelphia, PA. Dr. Morsy has several scientific publications and reviews in peer reviewed journals, including Nature Biotechnology, The Journal of Clinical Investigation (JCI), Proceedings of the National Academy of Sciences (PNAS), The Journal of the American Medical Association (JAMA), and Annual Review of Medicine (ARM).


Rakesh Ramachandran, MS, Vice President and Head of Information Technology and Communications

Mr. Ramachandran joined Athersys in 1997. He has served as Vice President and Head of Information Technology and Communications since January of 2017. He previously served as Director of Software Development and then as Director and Senior Director of IT and Communications.

Mr. Ramachandran received a BTech degree in Computer Science and Engineering from the Cochin University of Science and Technology, India and a MS in Computer Science from Case Western Reserve University, Cleveland.